A Critical Review of the Consensus Statement from the European Atherosclerosis Society Consensus Panel 2017.
- Harumi Okuyama,
- Tomohito Hamazaki,
- Rokuro Hama,
- Yoichi Ogushi,
- Tetsuyuki Kobayashi,
- Naoki Ohara,
- Hajime Uchino
Pharmacology 2018 Jan 19;101(3-4):184-218. Epub 2018 Jan 19.
Medical Corporation Uchinokai, Kumamoto, Japan.
Background: The Consensus Statement from the European Atherosclerosis Society (EAS) Consensus Panel 2017 concludes on the basis of 3 different types of clinical studies that low-density lipoprotein (LDL) causes atherosclerotic cardiovascular disease (ASCVD). In Mendelian randomization studies, rare genetic mutations affecting LDL receptor function were found to cause higher or lower LDL-C levels, which are associated with correspondingly altered ASCVD risk. In prospective cohort studies and randomized controlled trials (RCTs) of statins, a remarkably consistent log-linear association was demonstrated between the absolute magnitude of LDL-C exposure and ASCVD risk. Read More